Research
Hormonal
Metformin therapy reduces the incidence of new-onset type 2 diabetes in high-risk adults (BMI ≥35, age 25-59, fasting glucose ≥110 mg/dL, or prior gestational diabetes) and provides long-term cardiovascular and microvascular benefits.
If you are at high risk for type 2 diabetes (overweight, older than 25, or have a history of gestational diabetes), metformin can help prevent the disease. It is cost-effective and provides long-term benefits even after stopping the drug. Discuss with your doctor if you are a candidate, especially if lifestyle changes alone are insufficient.
StrongSupportsHIGH confidence
Metformin is recommended to prevent type 2 diabetes in adults aged 25–59 years, with BMI ≥ 35 kg/m2, fasting glucose ≥ 110 mg/dL, glycated hemoglobin ≥ 6.0%, and in women with prior gestational diabetes
Why this rating
Based on DPP/DPPOS data showing sustained benefit and cost-effectiveness.
Source
A Systematic Approach to Treating Early Metabolic Disease and Prediabetes
Nicholas W. Carris et al. · Diabetes Therapy · 2023
DOI 10.1007/s13300-023-01455-9
narrative_reviewCited 4×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Intensive lifestyle intervention (≥150 min/week moderate exercise and 500-1000 kcal/day caloric deficit) significantly reduces the incidence of new-onset type 2 diabetes compared to placebo, with benefits persisting for at least 21 years.Strong
- Systematic health system protocols, including consistent diagnosis and electronic health record decision support, are required to effectively treat early metabolic disease and prevent progression to advanced diabetes and cardiovascular disease.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →